What is the recommended Dulaglutide (Trulicity) dosage?

Dulaglutide (Trulicity) dosing varies by experience level. Beginners typically start at 0.75mg weekly, moderate users at 1.5mg weekly, and aggressive protocols use 4.5mg weekly.

How do you reconstitute Dulaglutide (Trulicity)?

Dulaglutide (Trulicity) comes as a pre-filled device — no reconstitution needed.

What is the half-life of Dulaglutide (Trulicity)?

The half-life of Dulaglutide (Trulicity) is ~5 days (120 hours). This determines how frequently you need to dose for consistent blood levels.

Dulaglutide (Trulicity)

Weight LossInjectionFDA ApprovedGrade A~5 days (120 hours) half-life

GLP-1 AgonistType 2 DiabetesCardiovascularWeight ManagementFDA-Approved

Benefits

FDA-approved for type 2 diabetes with proven glycemic control

Reduces major adverse cardiovascular events (REWIND trial: HR 0.88)

Convenient once-weekly pre-filled pen — no reconstitution required

Dose-dependent HbA1c reductions of 1.0-1.6% across AWARD trials

Promotes moderate weight loss (1.5-4.6 kg depending on dose)

Shown to slow eGFR decline and reduce new macroalbuminuria

Half-Life

~5 days

Route

Injection

Frequency

Weekly

Vial Sizes

0.75mg, 1.5mg, 3mg, 4.5mg

BAC Water

Pre-filled

Safety Grade

Grade A

Open Dulaglutide (Trulicity) Dosage Calculator

Calculate exact syringe units for your vial and dose

About Dulaglutide (Trulicity)

Dulaglutide (brand name Trulicity) is an FDA-approved GLP-1 receptor agonist manufactured by Eli Lilly for the treatment of type 2 diabetes and reduction of major adverse cardiovascular events. It is a fusion protein consisting of two GLP-1 analog sequences linked to a modified human IgG4 Fc domain, giving it a molecular weight of approximately 63 kDa and a half-life of about 5 days. This allows convenient once-weekly dosing via a pre-filled, single-use pen. The REWIND trial demonstrated a 12% reduction in major cardiovascular events over a median 5.4-year follow-up, making it the first GLP-1 agonist to show cardiovascular benefit in a population with and without established cardiovascular disease.

Who Should Consider Dulaglutide (Trulicity)

Adults with type 2 diabetes requiring improved glycemic control
Type 2 diabetics at elevated risk for major adverse cardiovascular events
Adults with type 2 diabetes and established cardiovascular disease
Patients seeking a once-weekly injectable with no reconstitution needed
Type 2 diabetics with moderate-to-severe chronic kidney disease (AWARD-7 data)
Adults who prefer a pre-filled pen over daily injectable GLP-1 therapies

How Dulaglutide (Trulicity) Works

Dulaglutide is a GLP-1 receptor agonist fusion protein. It consists of a GLP-1 analog (90% homologous to native GLP-1) covalently linked to a modified IgG4 Fc domain via a small peptide linker, forming a ~63 kDa homodimer. Upon binding GLP-1 receptors on pancreatic beta cells, it activates adenylyl cyclase, raising intracellular cAMP to stimulate glucose-dependent insulin secretion. It also suppresses inappropriately elevated glucagon from alpha cells, slows gastric emptying to blunt postprandial glucose spikes, and acts on hypothalamic satiety centers to reduce appetite. The IgG4 Fc domain reduces renal clearance and extends the half-life to approximately 5 days, supporting weekly dosing.

What to Expect

Weeks 1-4

0.75mg

Starting dose. GI side effects (nausea, diarrhea) are most common during this period and typically mild. Early blood sugar improvements begin. HbA1c reduction of approximately 0.5-0.7% expected. Appetite changes may start.

Weeks 5-8

1.5mg

First dose increase if glycemic targets are not met. GI effects often lessen as the body adjusts. HbA1c reductions of approximately 1.0-1.2% from baseline. Mild weight loss of 1-2 kg may occur.

Weeks 9-16

3.0mg if needed

Higher dose option available since AWARD-11. Further HbA1c reduction (up to 1.5% from baseline). Weight loss becomes more apparent. Steady-state drug levels are well established by this point.

Weeks 17-26

up to 4.5mg

Maximum dose. AWARD-11 showed HbA1c reductions up to 1.87% and weight loss of 4.6 kg at 36 weeks with 4.5mg. Fasting glucose and postprandial glucose control optimize. GI side effects generally resolved.

Week 26+

Long-term maintenance. REWIND trial showed sustained cardiovascular protection over 5.4 years of use. HbA1c and weight benefits are maintained while on therapy. Renal protective effects observed with prolonged use.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	0.75mg	Weekly
Moderate	1.5mg	Weekly
Aggressive	4.5mg	Weekly

Note: FDA-approved GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction. Delivered via pre-filled single-use pen (Trulicity). Titrate from 0.75mg weekly; may increase every 4 weeks. Max dose 4.5mg/week.

How to Inject Dulaglutide (Trulicity)

Administer once weekly via the pre-filled Trulicity pen. Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites with each dose. Can be administered at any time of day, with or without food. Take on the same day each week; the day may be changed if needed as long as the last dose was given 3 or more days prior. No reconstitution or needle attachment is required — the pen auto-injects upon activation.

Cycling Protocol

On Period

52 weeks

Off Period

0 weeks

Dulaglutide is used continuously as a chronic therapy for type 2 diabetes. No cycling is required or recommended. Discontinuation should be discussed with a prescribing physician, as glycemic control and cardiovascular benefits depend on ongoing use.

Pharmacokinetics

Half-Life

120h

Bioavailability

SC: ~47-65% (dose-dependent; 65% at 0.75mg, 47% at 1.5mg)

Tmax

~48 hours (range 24-72h)

Data Confidence

high

Source: FDA Prescribing Information (Trulicity), Section 12.3; Geiser et al. Clin Pharmacokinet 2016 PMID:26507721

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Nausea, diarrhea, vomiting, abdominal pain, and decreased appetite are the most common (affecting 8-21% of patients). GI side effects are dose-dependent and typically diminish with continued use. Rare but serious risks include pancreatitis, medullary thyroid carcinoma (boxed warning in rodent studies), and hypoglycemia when combined with insulin or sulfonylureas.

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
History of serious hypersensitivity reaction to dulaglutide or any product components
History of pancreatitis — use with caution; discontinue if pancreatitis is suspected
Pregnancy or breastfeeding — may cause fetal harm based on animal data; discontinue at least 2 months before planned pregnancy due to long washout
Severe gastrointestinal disease including gastroparesis
Type 1 diabetes or diabetic ketoacidosis — not indicated for these conditions

Drug Interactions

Insulin and sulfonylureas — increased risk of hypoglycemia; dose reduction of insulin or sulfonylurea may be needed
Oral medications — slowed gastric emptying may delay absorption of concomitant oral drugs
Warfarin — monitor INR more frequently when initiating or changing dulaglutide dose
Oral contraceptives — no clinically meaningful interaction observed, but consider potential delayed absorption
Levothyroxine — monitor thyroid levels as GI transit changes may alter absorption